BioTalk Unzipped30 Des 2024

Will FDA’s New LDT Rule Slow Drug Development? with Dr. Mark Arnold

In this episode of BioTalk Unzipped, host Gregory Austin and co-host Chad Briscoe engage with Dr. Mark Arnold, a distinguished bioanalytical thought leader. They discuss the impact of recent FDA regulations on drug development, the importance of community support through the Samaritan Purse charity, especially on recent hurricane victims, and the exciting advancements in RNA editing technologies. The conversation highlights the collaborative nature of the pharmaceutical industry and the drive behind bioanalytical work, emphasizing the ultimate goal of delivering effective therapies to patients.

Chapters

00:00 Introduction to BioTalk Unzipped at AAPS PharmSci 360

03:45 Samaritan's Purse Charity and Community Impact

05:16 Most impactful talk at AAPS?

11:50 Comparative Analysis of FDA and EU Regulations

17:37 The Drive Behind Bioanalytical Work

22:24 NEW NEWS! - Innovations in RNA Editing and Bioanalysis

Takeaways

The FDA's new rules on lab-developed tests could delay biomarker utilization in clinical trials.
Community support through charities like Samaritan's Purse is crucial during crises.
The importance of collaboration in advancing drug development and bioanalytical methods.
Innovations in RNA editing present new bioanalytical challenges.
The drive to help patients is a key motivator for professionals in the field.

Sound Bites

"I worked on that drug and there's a clear benefit."
"It's getting that new therapy to a patient."
"This is going to change and potentially delay biomarkers."

New News Story:

Wave sees RNA editing validation in early trial results

◦https://www.biopharmadive.com/news/wave-rna-editing-aatd-first-trial-data/729981/

How to reach us:

Please donate to: Samaritan’s Purse

https://www.samaritanspurse.org/

Mark Arnold

https://www.linkedin.com/in/markearnoldphd/

Blog - https://bioanalysisandbiomarkers.blogspot.com/

Dr. Chad Briscoe

https://www.linkedin.com/in/chadbriscoe/

Gregory Austin

https://www.linkedin.com/in/gregoryaustin1/

Image Credits

AAPS

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(45)

Why Gene Therapy Is Still So Hard to Manufacture at Scale | Phillip Ramsey

Why is gene therapy still so difficult to manufacture at scale after decades of progress?Phillip Ramsey, Chief Technical Officer at Sangamo Therapeutics, joins BioTalk Unzipped for a candid conversati...

8 Aug 11min

Her Daughter’s Brain Tumor Turned Her Into a Biotech Founder | Tracy Ryan

A mother’s search for answers to her daughter’s relentless brain tumor led her into natural killer cell biology, cancer immunotherapy, and biotech entrepreneurship.Sponsored by Leucentra, https://leuc...

20 Jul 1h 4min

The Future of Oncology Drug Development | Dr. Lakshmi Amaravadi

Oncology drug development is becoming more complex, and bioanalysis can no longer be treated as simple drug measurement.Sponsored by Leucentra, https://leucentra.com/Inspired by science, empowered by ...

11 Jun 29min

Active Machine Learning for Drug Discovery & Nanomedicine with Dr. Daniel Reker

Can artificial intelligence help make cancer therapies safer, more targeted, and more effective?In this episode of BioTalk Unzipped, Gregory Austin sits down with Dr. Daniel Reker, Assistant Professor...

25 Apr 50min

Why Haven’t We Cured Cancer Yet? | Dr. Bob Liu Explains

Why haven’t we cured cancer yet? A Genentech scientist explains the real reason.In this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe sit down with Dr. Bob Liu, Senior Principal Sci...

19 Mar 1h

The Intersection of Biotech, Patent Law, and AI with Dr. Kate Neville, IP Attorney

Recorded October 31, 2025In this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe sit down with Dr. Kate Neville, immunologist turned seasoned biotech patent attorney at Marshall, Gers...

16 Feb 52min

Long-acting Cell-Based Gene Therapy, Fabry Disease and Beyond with Glafabra CEO, Dr. Chris Hopkins

In this episode of BioTalk Unzipped, hosts Gregory Austin and Dr. Chad Briscoe sit down with Glafabra CEO: Dr. Chris Hopkins, geneticist, biochemist, and biotech entrepreneur, to explore the science a...

22 Des 202549min

Fail Fast, Learn Faster: Drug Development in Rare Disease with Dr. Binodh DeSilva

In this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe sit down with Dr. Binodh DeSilva, Senior Vice President of Bioanalysis at Ultragenyx Pharmaceutical, to explore the science and...

23 Okt 202531min